Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
- Peter Lynch
What is insider trading>>
| UNITED STATES | ||
| SECURITIES AND EXCHANGE COMMISSION | ||
| Washington, D.C. 20549 |
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Ambrx Biopharma Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
641871108
(CUSIP Number)
December 31, 2023
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| ¨ | Rule 13d-1(b) |
| ¨ | Rule 13d-1(c) |
| x | Rule 13d-1(d) |
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 641871108 |
| 1. | Names of Reporting Persons WuXi AppTec (Hong Kong) Holding Limited | |
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) | |
| (a) | ¨ | |
| (b) | x (1) | |
| 3. | SEC Use Only | |
| 4. | Citizenship or Place of Organization Hong Kong, China | |
| Number
of Shares Beneficially Owned by Each Reporting Person With |
5. | Sole Voting Power 0 |
| 6. | Shared Voting Power 0 | |
| 7. | Sole Dispositive Power 0 | |
| 8. | Shared Dispositive Power 0 | |
| 9. | Aggregate
Amount Beneficially Owned by Each Reporting Person 0 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
| 11. | Percent of Class Represented by Amount in Row (9) 0.0% |
| 12. | Type of Reporting Person (See Instructions) OO |
| (1) | This Schedule 13G is filed by WuXi AppTec (Hong Kong) Holding Limited (“AppTec HK”), WuXi PharmaTech Healthcare Fund I L.P. (“PharmaTech”) and WuXi AppTec Co., Ltd. (“AppTec Co” and, with AppTec HK and PharmaTech, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G. |
2
| CUSIP No. 641871108 |
| 1. | Names of Reporting Persons WuXi PharmaTech Healthcare Fund I L.P. | |
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) | |
| (a) | ¨ | |
| (b) | x (1) | |
| 3. | SEC Use Only | |
| 4. | Citizenship or Place of Organization Cayman Islands | |
| Number
of Shares Beneficially Owned by Each Reporting Person With |
5. | Sole Voting Power 0 |
| 6. | Shared Voting Power 1,000,000 shares (2) | |
| 7. | Sole Dispositive Power 0 | |
| 8. | Shared Dispositive Power 1,000,000 shares (2) | |
| 9. | Aggregate
Amount Beneficially Owned by Each Reporting Person 1,000,000 shares (2) |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
| 11. | Percent of Class Represented by Amount in Row (9) 1.6% (3) |
| 12. | Type of Reporting Person (See Instructions) PN |
| (1) | This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G. | |
| (2) | Shares are directly held by PharmaTech. PharmaTech is an indirect, wholly owned subsidiary of AppTec Co, which is the ultimate beneficial owner of PharmaTech and shares voting and investment authority over these shares. | |
| (3) | This calculation is based on 63,150,244 shares of common stock outstanding as of November 9, 2023, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 13, 2023. |
3
| CUSIP No. 641871108 |
| 1. | Names of Reporting Persons WuXi AppTec Co., Ltd. | |
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) | |
| (a) | ¨ | |
| (b) | x (1) | |
| 3. | SEC Use Only | |
| 4. | Citizenship or Place of Organization Mainland China | |
| Number
of Shares Beneficially Owned by Each Reporting Person With |
5. | Sole Voting Power 0 |
| 6. | Shared Voting Power 1,000,000 shares (2) | |
| 7. | Sole Dispositive Power 0 | |
| 8. | Shared Dispositive Power 1,000,000 shares (2) | |
| 9. | Aggregate
Amount Beneficially Owned by Each Reporting Person 1,000,000 shares (2) |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
| 11. | Percent of Class Represented by Amount in Row (9) 1.6% (3) |
| 12. | Type of Reporting Person (See Instructions) OO |
| (1) | This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G. | |
| (2) | Shares are held directly by PharmaTech. AppTec Co is the indirect parent company, and ultimate beneficial owner, of each of AppTec HK and PharmaTech and shares voting and investment authority over these shares. | |
| (3) | This calculation is based on 63,150,244 shares of common stock outstanding as of November 9, 2023, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 13, 2023. |
4
| Item 1. | ||
| (a) | Name of Issuer Ambrx Biopharma Inc. (the “Issuer”) | |
| (b) | Address of Issuer’s Principal Executive Offices 10975 Torrey Pines Road, La Jolla, California 92037 | |
| Item 2. | ||
| (a) | Name of Person Filing WuXi AppTec (Hong Kong) Holding Limited (“AppTec HK”) WuXi PharmaTech Healthcare Fund I L.P. (“PharmaTech”) WuXi AppTec Co., Ltd. (“AppTec Co”) | |
| (b) | Address of Principal Business Office or, if none, Residence 288 Fute Zhong Road Pudong New Area Shanghai 200131, China | |
| (c) | Citizenship AppTec HK - Hong Kong, China PharmaTech - Cayman Islands AppTec Co - Mainland China | |
| (d) | Title of Class of Securities Common Stock, par value $0.0001 per share (the “Common Stock”) | |
| (e) | CUSIP Number 641871108 | |
| Item 3. | If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
| Not applicable | ||
5
| Item 4. | Ownership |
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
| Reporting Persons | Shares Held Directly | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Beneficial Ownership | Percentage of Class (2) | |||||||||||||||||||||
| AppTec HK | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | % | ||||||||||||||||||||
| PharmaTech (1) | 1,000,000 | 0 | 1,000,000 | 0 | 1,000,000 | 1,000,000 | 1.6 | % | ||||||||||||||||||||
| AppTec Co (1) | 0 | 0 | 1,000,000 | 0 | 1,000,000 | 1,000,000 | 1.6 | % | ||||||||||||||||||||
| (1) | Includes 1,000,000 shares held directly held by ParmaTech. AppTec Co is the indirect parent company, and ultimate beneficial owner, of PharmaTech and shares voting and investment authority over these shares. |
| (2) | This calculation is based on 63,150,244 shares of common stock outstanding as of November 9, 2023, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 13, 2023. |
| Item 5. | Ownership of Five Percent or Less of a Class |
| If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x. | |
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person |
| Not applicable | |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person |
| Not applicable | |
| Item 8. | Identification and Classification of Members of the Group |
| Not applicable | |
| Item 9. | Notice of Dissolution of Group |
| Not applicable | |
| Item 10. | Certification |
| Not applicable |
6
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 5, 2024
WuXi AppTec (Hong Kong) Holding Limited
| By: | /s/ Edward Hu | |
| Name: Edward Hu | ||
| Title: Director |
WuXi PharmaTech Healthcare Fund I L.P.
| By: | /s/ Edward Hu | |
| Name: Edward Hu | ||
| Title: Director |
WuXi AppTec Co., Ltd.
| By: | /s/ Edward Hu | |
| Name: Edward Hu | ||
| Title: Director |
| ATTENTION | ||
| Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001). | ||
7
Exhibit(s):
A - Joint Filing Statement
8
EXHIBIT A
JOINT FILING STATEMENT
We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Ambrx Biopharma Inc. is filed on behalf of each of us.
Dated: February 5, 2024
WuXi AppTec (Hong Kong) Holding Limited
| By: | /s/ Edward Hu | |
| Name: Edward Hu | ||
| Title: Director |
WuXi PharmaTech Healthcare Fund I L.P.
| By: | /s/ Edward Hu | |
| Name: Edward Hu | ||
| Title: Director |
WuXi AppTec Co., Ltd.
| By: | /s/ Edward Hu | |
| Name: Edward Hu | ||
| Title: Director |